LS
NKTR icon

Lupo Securities’s Nektar Therapeutics NKTR Stock Holding History

Lupo Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$14K Buy
87
+20
+30% +$3.54K 0.11% 62
2015
Q2 		$13K Sell
67
-20
-23% -$3.44K 0.05% 54
2015
Q1 		$14K Buy
+87
New +$17.9K 0.02% 267

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lupo Securities's NKTR Position: Q3 2015 in Review

Lupo Securities increased its Nektar Therapeutics (NKTR) stake by 30% in Q3 2015, buying an estimated $3.54K and bringing the position to 87 shares worth $14K. The position accounts for 0.11% of the portfolio, ranked #62.

Lupo Securities first reported a position in NKTR in Q1 2015 and has held it in 3 quarters since. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

  • Lupo Securities held 87 shares of Nektar Therapeutics worth $14K as of Q3 2015.
  • Lupo Securities bought 20 Nektar Therapeutics shares in Q3 2015, an estimated $3.54K.
  • Nektar Therapeutics made up 0.11% of Lupo Securities's portfolio in Q3 2015, its #62 holding.
  • Lupo Securities first reported a position in Nektar Therapeutics in Q1 2015 and has held it in 3 quarters since.
  • 166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Lupo Securities's 13F filing for Q3 2015, filed 13 Nov 2015.